08.25.25 -- Advancing ADCs: New Payloads, Faster Timelines, Better Control

ADCs combine antibody targeting with potent cytotoxic payloads, but their complexity requires phase-appropriate analytical strategies spanning DAR measurement, impurity control, and hybrid biologic–chemical characterization to ensure consistency, safety, and efficacy.

We want to empower drug developers to freely evaluate two novel ADC payloads for their ADC antibodies without financial burdens or medicinal chemistry expertise. Discover these payloads and how you can test them for your needs through our Easy to Access Technology program.

Follow along as Derrick Katayama, Lead Scientist of Formulation Development at Samsung Biologics, explores the key challenges faced during biopharmaceutical studies and highlights the latest techniques and innovative solutions that can help overcome these obstacles.